The Dynamic Neuroendocrine Response to Critical Illness

Endocrinology and Metabolism Clinics of North America

Volumn 35, Issue 4, 2006, Pages 777-791

  Langouche, Lies ^a   Van den Berghe, Greet ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; DOPAMINE; FATTY ACID; FOLLITROPIN; GLUCOCORTICOID; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; LUTEINIZING HORMONE; PRALMORELIN; PROLACTIN; PROTIRELIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN; THYROID HORMONE; THYROTROPIN; TRANSCORTIN; TUMOR NECROSIS FACTOR ALPHA;

ADENOHYPOPHYSIS; BLOOD GLUCOSE MONITORING; BRAIN DYSFUNCTION; CLINICAL TRIAL; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISEASE COURSE; DRUG MEGADOSE; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INNATE IMMUNITY; INTENSIVE CARE UNIT; LOW DRUG DOSE; METABOLIC DISORDER; NEUROENDOCRINE DISEASE; NEUROENDOCRINE SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THYROID HORMONE METABOLISM; UNSPECIFIED SIDE EFFECT;

CRITICAL CARE; CRITICAL ILLNESS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEUROSECRETORY SYSTEMS; PITUITARY-ADRENAL SYSTEM; THYROID GLAND;

EID: 33751217686     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2006.09.007     Document Type: Review

References (93)

1. Takala J., Ruokonen E., Webster N.R., et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341 (1999) 785-792
2. Roberts I., Yates D., Sandercock P., et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 364 (2004) 1321-1328
3. Van den Berghe G., de Zegher F., et al. Clinical review 95: acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 83 (1998) 1827-1834
4. Weekers F., Van Herck E., Coopmans W., et al. A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. Endocrinology 143 (2002) 764-774
5. Debaveye Y., and Van den Berghe G. Is there still a place for dopamine in the modern intensive care unit?. Anesth Analg 98 (2004) 461-468
6. Cummings D.E., and Merriam G.R. Growth hormone therapy in adults. Annu Rev Med 54 (2003) 513-533
7. Van den Berghe G., Baxter R.C., Weekers F., et al. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 85 (2000) 183-192
8. Bowers C.Y., Momany F.A., Reynolds G.A., et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114 (1984) 1537-1545
9. Howard A.D., Feighner S.D., Cully D.F., et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273 (1996) 974-977
10. Kojima M., Hosoda H., Date Y., et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
11. Ross R., Miell J., Freeman E., et al. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 35 (1991) 47-54
12. Baxter R.C., Hawker F.H., To C., et al. Thirty-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients. Growth Horm IGF Res 8 (1998) 455-463
13. Hermansson M., Wickelgren R.B., Hammarqvist F., et al. Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery. J Clin Endocrinol Metab 82 (1997) 421-428
14. Defalque D., Brandt N., Ketelslegers J.M., et al. GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. Am J Physiol 276 (1999) E565-E572
15. Van den Berghe G., de Zegher F., Veldhuis J.D., et al. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 82 (1997) 590-599
16. Van den Berghe G., de Zegher F., Baxter R.C., et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 83 (1998) 309-319
17. Van den Berghe G., Wouters P., Weekers F., et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 84 (1999) 1311-1323
18. Yen P.M. Physiological and molecular basis of thyroid hormone action. Physiol Rev 81 (2001) 1097-1142
19. Bianco A.C., Salvatore D., Gereben B., et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23 (2002) 38-89
20. Friesema E.C., Jansen J., and Visser T.J. Thyroid hormone transporters. Biochem Soc Trans 33 (2005) 228-232
21. Michalaki M., Vagenakis A.G., Makri M., et al. Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNFalpha in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 86 (2001) 4198-4205
22. Van den Berghe G. Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol 143 (2000) 1-13
23. Romijn J.A., and Wiersinga W.M. Decreased nocturnal surge of thyrotropin in nonthyroidal illness. J Clin Endocrinol Metab 70 (1990) 35-42
24. McIver B., and Gorman C.A. Euthyroid sick syndrome: an overview. Thyroid 7 (1997) 125-132
25. Rothwell P.M., and Lawler P.G. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 23 (1995) 78-83
26. Rothwell P.M., Udwadia Z.F., and Lawler P.G. Thyrotropin concentration predicts outcome in critical illness. Anaesthesia 48 (1993) 373-376
27. Boelen A., Platvoet-ter Schiphorst M.C., Bakker O., et al. The role of cytokines in the lipopolysaccharide-induced sick euthyroid syndrome in mice. J Endocrinol 146 (1995) 475-483
28. Van der Poll T., Romijn J.A., Wiersinga W.M., et al. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 71 (1990) 1567-1572
29. Van der Poll T., Van Zee K.J., Endert E., et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab 80 (1995) 1341-1346
30. Van der Poll T., Endert E., Coyle S.M., et al. Neutralization of TNF does not influence endotoxininduced changes in thyroid hormone metabolism in humans. Am J Physiol 276 (1999) R357-R362
31. Lim C.F., Docter R., Visser T.J., et al. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesterified fatty acids. J Clin Endocrinol Metab 76 (1993) 1165-1172
32. Gardner D.F., Kaplan M.M., Stanley C.A., et al. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med 300 (1979) 579-584
33. De Groot L.J. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 84 (1999) 151-164
34. Van den Berghe G., de Zegher F., Veldhuis J.D., et al. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf) 47 (1997) 599-612
35. Peeters R.P., Wouters P.J., van Toor H., et al. Serum rT3 and T3/rT3 are prognostic markers in critically ill patients and are associated with post-mortem tissue deiodinase activities. J Clin Endocrinol Metab 90 8 (2005) 4559-4561
36. Fliers E., Guldenaar S.E., Wiersinga W.M., et al. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab 82 (1997) 4032-4036
37. Damas P., Reuter A., Gysen P., et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17 (1989) 975-978
38. Van den Berghe G., de Zegher F., and Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol (Oxf) 41 (1994) 731-737
39. Faglia G., Ferrari C., Beck-Peccoz P., et al. Reduced plasma thyrotropin response to thyrotropin releasing hormone after dexamethasone administration in normal subjects. Horm Metab Res 5 (1973) 289-292
40. Peeters R.P., Wouters P.J., Kaptein E., et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88 (2003) 3202-3211
41. Weekers F., Michalaki M., Coopmans W., et al. Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. Endocrinology 145 (2004) 205-213
42. Debaveye Y., Ellger B., Mebis L., et al. Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2. Endocrinology 146 (2005) 5604-5611
43. Timmer DC, Peeters RP, Wouters P, et al. Thyroid hormone receptor alpha splice variants in livers of critically ill patients. Thyroid, in press.
44. Spratt D.I. Altered gonadal steroidogenesis in critical illness: is treatment with anabolic steroids indicated?. Best Pract Res Clin Endocrinol Metab 15 (2001) 479-494
45. Ben Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocr Rev 6 (1985) 564-589
46. Samson W.K., Taylor M.M., and Baker J.R. Prolactin-releasing peptides. Regul Pept 114 (2003) 1-5
47. Wang C., Chan V., and Yeung R.T. Effect of surgical stress on pituitary-testicular function. Clin Endocrinol (Oxf) 9 (1978) 255-266
48. Wang C., Chan V., Tse T.F., et al. Effect of acute myocardial infarction on pituitary-testicular function. Clin Endocrinol (Oxf) 9 (1978) 249-253
49. Dong Q., Hawker F., McWilliam D., et al. Circulating immunoreactive inhibin and testosterone levels in men with critical illness. Clin Endocrinol (Oxf) 36 (1992) 399-404
50. Rivier C., Vale W., and Brown M. In the rat, interleukin-1 alpha and -beta stimulate adrenocorticotropin and catecholamine release. Endocrinology 125 (1989) 3096-3102
51. Guo H., Calkins J.H., Sigel M.M., et al. Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis. Endocrinology 127 (1990) 1234-1239
52. Noel G.L., Suh H.K., Stone J.G., et al. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab 35 (1972) 840-851
53. Vogel A.V., Peake G.T., and Rada R.T. Pituitary-testicular axis dysfunction in burned men. J Clin Endocrinol Metab 60 (1985) 658-665
54. Woolf P.D., Hamill R.W., McDonald J.V., et al. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 60 (1985) 444-450
55. Van den Berghe G., de Zegher F., Lauwers P., et al. Luteinizing hormone secretion and hypoandrogenaemia in critically ill men: effect of dopamine. Clin Endocrinol (Oxf) 41 (1994) 563-569
56. Van den Berghe G., Weekers F., Baxter R.C., et al. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. J Clin Endocrinol Metab 86 (2001) 3217-3226
57. Cicero T.J., Bell R.D., Wiest W.G., et al. Function of the male sex organs in heroin and methadone users. N Engl J Med 292 (1975) 882-887
58. Meakins J.L., Pietsch J.B., Bubenick O., et al. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 186 (1977) 241-250
59. Devins S.S., Miller A., Herndon B.L., et al. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med 20 (1992) 1644-1649
60. Cooper M.S., and Stewart P.M. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348 (2003) 727-734
61. Burchard K. A review of the adrenal cortex and severe inflammation: quest of the "eucorticoid" state. J Trauma 51 (2001) 800-814
62. Rivier C., and Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 305 (1983) 325-327
63. Pemberton P.A., Stein P.E., Pepys M.B., et al. Hormone binding globulins undergo serpin conformational change in inflammation. Nature 336 (1988) 257-258
64. Hammond G.L., Smith C.L., Paterson N.A., et al. A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab 71 (1990) 34-39
65. Beishuizen A., Thijs L.G., and Vermes I. Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 27 (2001) 1584-1591
66. Hamrahian A.H., Oseni T.S., and Arafah B.M. Measurements of serum free cortisol in critically ill patients. N Engl J Med 350 (2004) 1629-1638
67. Vanhorebeek I., Peeters R.P., Vander Perre S., et al. Cortisol response to critical illness: effect of intensive insulin therapy. J Clin Endocrinol Metab 91 10 (2006) 3803-3813
68. Marik P.E., and Zaloga G.P. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 122 (2002) 1784-1796
69. Finlay W.E., and McKee J.I. Serum cortisol levels in severely stressed patients. Lancet 1 (1982) 1414-1415
70. Rothwell P.M., Udwadia Z.F., and Lawler P.G. Cortisol response to corticotropin and survival in septic shock. Lancet 337 (1991) 582-583
71. Span L.F., Hermus A.R., Bartelink A.K., et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 18 (1992) 93-96
72. Annane D., Sebille V., Troche G., et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283 (2000) 1038-1045
73. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002) 862-871
74. Sam S., Corbridge T.C., Mokhlesi B., et al. Cortisol levels and mortality in severe sepsis. Clin Endocrinol (Oxf) 60 (2004) 29-35
75. Bornstein S.R., and Chrousos G.P. Clinical review 104: adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 84 (1999) 1729-1736
76. Vermes I., and Beishuizen A. The hypothalamic-pituitary-adrenal response to critical illness. Best Pract Res Clin Endocrinol Metab 15 (2001) 495-511
77. Barquist E., and Kirton O. Adrenal insufficiency in the surgical intensive care unit patient. J Trauma 42 (1997) 27-31
78. Streat S.J., Beddoe A.H., and Hill G.L. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. J Trauma 27 (1987) 262-266
79. Russell-Jones D.L., Umpleby A.M., Hennessy T.R., et al. Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans. Am J Physiol 267 (1994) E591-E598
80. Minneci P.C., Deans K.J., Banks S.M., et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141 (2004) 47-56
81. Stathatos N., Levetan C., Burman K.D., et al. The controversy of the treatment of critically ill patients with thyroid hormone. Best Pract Res Clin Endocrinol Metab 15 (2001) 465-478
82. Ferrando A.A., Sheffield-Moore M., Wolf S.E., et al. Testosterone administration in severe burns ameliorates muscle catabolism. Crit Care Med 29 (2001) 1936-1942
83. Angele M.K., Ayala A., Cioffi W.G., et al. Testosterone: the culprit for producing splenocyte immune depression after trauma hemorrhage. Am J Physiol 274 (1998) C1530-C1536
84. Van den Berghe G., Baxter R.C., Weekers F., et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 56 (2002) 655-669
85. Langouche L., and Van den Berghe G. Glucose metabolism and insulin therapy. Crit Care Clin 22 (2006) 119-129 [vii.]
86. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001) 1359-1367
87. Van den Berghe G., Schoonheydt K., Becx P., et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 64 (2005) 1348-1353
88. Van den Berghe G., Wouters P.J., Bouillon R., et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31 (2003) 359-366
89. Hansen T.K., Thiel S., Wouters P.J., et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88 (2003) 1082-1088
90. Langouche L., Vanhorebeek I., Vlasselaers D., et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 115 (2005) 2277-2286
91. Vanhorebeek I., De Vos R., Mesotten D., et al. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 365 (2005) 53-59
92. Weekers F., Giulietti A.P., Michalaki M., et al. Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology 144 (2003) 5329-5338
93. Van den Berghe G., Wilmer A., Hermans G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 (2006) 449-461